These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38157867)

  • 21. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.
    Wang YX; Pettus M; Gao D; Phillips C; Scott Bowersox S
    Pain; 2000 Feb; 84(2-3):151-8. PubMed ID: 10666519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.
    Wermeling DP
    Pharmacotherapy; 2005 Aug; 25(8):1084-94. PubMed ID: 16207099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.
    Wang YX; Gao D; Pettus M; Phillips C; Bowersox SS
    Pain; 2000 Feb; 84(2-3):271-81. PubMed ID: 10666532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
    Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
    Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker.
    Koganei H; Shoji M; Iwata S
    Biol Pharm Bull; 2009 Oct; 32(10):1695-700. PubMed ID: 19801830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of intrathecal ziconotide for the treatment of chronic pain.
    Jain KK
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2403-10. PubMed ID: 11060815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure changes after intrathecal co-administration of calcium channel blockers with morphine or clonidine at the spinal level.
    Horvath G; Brodacz B; Holzer-Petsche U
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):270-5. PubMed ID: 12172710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The alpha2delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Cav2.2) calcium channels.
    Mould J; Yasuda T; Schroeder CI; Beedle AM; Doering CJ; Zamponi GW; Adams DJ; Lewis RJ
    J Biol Chem; 2004 Aug; 279(33):34705-14. PubMed ID: 15166237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of human Ca
    Gao S; Yao X; Yan N
    Nature; 2021 Aug; 596(7870):143-147. PubMed ID: 34234349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziconotide: a new option for refractory pain.
    Prommer E
    Drugs Today (Barc); 2006 Jun; 42(6):369-78. PubMed ID: 16845440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-type calcium channel blockers: novel therapeutics for the treatment of pain.
    Schroeder CI; Doering CJ; Zamponi GW; Lewis RJ
    Med Chem; 2006 Sep; 2(5):535-43. PubMed ID: 17017994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N- and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain.
    Yamamoto S; Suzuki Y; Ono H; Kume K; Ohsawa M
    Eur J Pharmacol; 2016 Dec; 793():66-75. PubMed ID: 27823932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioactive Mimetics of Conotoxins and other Venom Peptides.
    Duggan PJ; Tuck KL
    Toxins (Basel); 2015 Oct; 7(10):4175-98. PubMed ID: 26501323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressant-like and memory-enhancing effects of the N-type calcium channel blocker ziconotide in rats.
    Bozorgi H; Budde T; Nankali M
    Behav Brain Res; 2020 Jul; 390():112647. PubMed ID: 32428635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoradiographic localization of N-type VGCCs in gerbil hippocampus and failure of omega-conotoxin MVIIA to attenuate neuronal injury after transient cerebral ischemia.
    Azimi-Zonooz A; Kawa CB; Dowell CD; Olivera BM
    Brain Res; 2001 Jul; 907(1-2):61-70. PubMed ID: 11430886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex-dependent Cav2.3 channel contribution to the secondary hyperalgesia in a mice model of central sensitization.
    Ferreira MA; Lückemeyer DD; Macedo-Júnior SJ; Schran RG; Silva AM; Prudente AS; Tonello R; Ferreira J
    Brain Res; 2021 Aug; 1764():147438. PubMed ID: 33753067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiological evidence for voltage-gated calcium channel 2 (Cav2) modulation of mechano- and thermosensitive spinal neuronal responses in a rat model of osteoarthritis.
    Rahman W; Patel R; Dickenson AH
    Neuroscience; 2015 Oct; 305():76-85. PubMed ID: 26247695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel mechanism of voltage-gated N-type (Cav2.2) calcium channel inhibition revealed through α-conotoxin Vc1.1 activation of the GABA(B) receptor.
    Huynh TG; Cuny H; Slesinger PA; Adams DJ
    Mol Pharmacol; 2015 Feb; 87(2):240-50. PubMed ID: 25425625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
    Kolosov A; Goodchild CS; Cooke I
    Pain Med; 2010 Feb; 11(2):262-73. PubMed ID: 20002322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of effects of T and N type calcium channel blockers on the electroencephalogram recordings in Wistar Albino Glaxo/Rij rats, an absence epilepsy model.
    Durmus N; Gültürk S; Kaya T; Demir T; Parlak M; Altun A
    Indian J Pharmacol; 2015; 47(1):34-8. PubMed ID: 25821308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.